Already a reality in flexible endoscopy, multi-spectral lighting could revolutionise
tomorrow‘s operating theatres. PHOTONIC contributes the necessary development know-how and manufacturing expertise to actively shape this change.

So far, the application of multispectral lighting has been limited to diagnostic endoscopy, especially to gastroscopy and  colonoscopy, using flexible endoscopes. With this technology, which is currently available only in high-end systems, it is possible to highlight vascular structures with greater contrast, render subepithelial vessels visible, improve the detection of bleeding and penetrate into deeper tissue layers.

In contrast, surgical endoscopy overwhelmingly relies on white light, which can be supported or replaced by near-infrared light in certain stages of surgery. Meanwhile, this method has been established as the gold standard. Yet PHOTONIC firmly believes that this restriction to a dual spectrum has an expiry date. ”Applying the principle of multispectral lighting from diagnostics to surgical endoscopy as an addition to established procedures opens completely new opportunities in intraoperative visualisation“, says Business Developer Ingo Wiest. This can enhance the rendering of blood vessels and structures during surgery, further improving safety and precision in operating theatres.

Why is PHOTONIC already capable of venturing into this with potential customers? Because the company possesses the necessary knowledge, experience and clearly structured processes – from spectral analysis and the selection of suitable emitters and filters through optical design to prototyping and tests in its in-house laboratory. Up to 7-channel concepts have been  developed here, flexibly combining LED and diode lasers.

During development, PHOTONIC simulates optical paths using raytracing, integrates digital twins of optical components and optimises imaging quality, stability and beam profile. An iterative control circuit with sensitivity and tolerance analyses ensures that critical parameters are stabilised and solutions are continuously fine-tuned. The result are state-of-the-art systems, which are at the same time designed to meet exact parameters like space, interfaces or costs. Moreover, having secured FDA registration for all its manufacturing sites, PHOTONIC also meets all regulatory requirements to implement projects for the US market.

A STEP AHEAD
Wiest points out to another major advantage: the company‘s close partnership with renowned manufacturers. ”We get samples of the latest light sources before they officially reach the market. This secures a decisive headstart, allowing us to get our customers‘ products ready for the market much faster.“